Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (2022${count})

  • Outcome Measures, 2021
    Assessing Parkinson’s at Home: Contactless Monitoring of Sleep, Motor Symptom Progression and Medication Response

    Study Rationale:
    The ability to accurately monitor Parkinson’s disease (PD) progression and medication response at home can significantly benefit disease management and drug development. In the past...

  • Therapeutic Pipeline Program, 2021
    Harnessing the ADAR Protein to Repair the LRRK2 Mutation Causing Parkinson's Disease

    Study Rationale:    
    The majority of cases of inherited Parkinson’s disease (PD) are caused by a single-letter change in the gene that encodes the LRRK2 protein. The mutation, which changes a G to an...

  • Therapeutic Pipeline Program, 2021
    Evaluating the Safety, Tolerability and Potential Efficacy of SB-0107 for Treating Parkinson’s Disease and Levodopa-Induced Dyskinesia

    Study Rationale:
    Although levodopa is an effective treatment for Parkinson’s disease (PD), its ability to activate dopamine D1 receptors also leads to its most vexing side effect: dyskinesia. An...

  • Therapeutic Pipeline Program, 2021
    Using Ketamine to Treat Depression in Parkinson’s Disease

    Study Rationale:
    Depression affects around half of people with Parkinson’s disease (PD). However, existing antidepressants are not effective in treating these symptoms in PD and new treatments are...

  • Analysis of Patient-Reported Outcomes from Fox Insight, 2021
    Overcoming Underrepresentation to Improve Generalizability in Fox Insight

    Study Rationale:
    Fox Insight is an online clinical study that surveys over 25,000 people with Parkinson disease (PD) about their overall health, symptoms and well-being. Unfortunately, certain...

  • Therapeutic Pipeline Program, 2021
    Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease

    Study Rationale:
    Previous studies have shown that fat molecules called unsaturated fatty acids regulate the harmful effects that alpha-synuclein have on neurons. This protein forms a key part of Lewy...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.